AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback